Healthcare
Stevanato Group S.p.A.(STVN)
Live Price
Offline$17.54
+2.81% today
1Y Change
-29.56%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $4.12B
- Revenue Growth
- +3.2%
- EPS Growth
- +14.0%
- Dividend Yield
- 0.3%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stevanato Group S.p.A. (STVN) is a Healthcare stock with a market cap of $4.12B and listed on NYSE. The stock last traded around $17.54 and down 29.6% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +3.2%, EPS growth of +14.0%, a dividend yield of 0.3%. What stands out right now is revenue +3.2%, EPS +14.0%, free cash flow +113.6% with operating margin 16.5% and ROIC 6.8%. The dividend is present but secondary, with a yield around 0.3%. Valuation is more restrained than many high-expectation growth names at P/E 29.5 and price/sales 3.5. Stock Foundry combines STVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.2% vs +7.6% peer median
Operating Margin
Below sector median
+16.5% vs +19.4% peer median
P/E
Below sector median
29.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.2% and EPS at +14.0%, with operating margin around 16.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +1.1% | -0.2% | +2.4% |
2026 Mar 4, 2026 | +5.0% | -9.1% | -13.1% | -21.4% |
2025 Nov 6, 2025 | +14.3% | -1.3% | -7.2% | -9.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STVN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STVN Max Drawdown
-51.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STVN and SPY.
Company Overview
Stevanato Group S.p.A.
New York Stock Exchange
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.
- Leadership
- Franco Stevanato
- IPO Date
- Jul 16, 2021
- Employees
- 5.5k
- Street Address
- Via Molinella, 17
- Mailing
- Piombino Dese, PD, 35017
- Region
- Piombino Dese, PD, IT
- Reporting Currency
- USD
- Investor Line
- 39 04 99 31 811
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.5
- EV/EBITDA
- 15.8
- Price/Sales
- 3.5
- Price/Book
- 2.8
Growth
- Revenue
- +3.2%
- EPS
- +14.0%
- Free Cash Flow
- +113.6%
Profitability
- Gross Margin
- 29.0%
- Operating Margin
- 16.5%
- Net Margin
- 11.8%
- ROE
- 9.7%
- ROIC
- 6.8%
Balance Sheet
- Debt/Equity
- 0.32
- Current Ratio
- 1.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.